KBY Biotech Indexv0.0.34
Search
← Pipeline|EXA-3015

EXA-3015

Phase 1
By Exact Sciences
Source: Trial-derived·Trials: 2
Modality
ERT
MOA
FXIai
Target
APOC3
Pathway
Wnt
Endometrial CaAngelmanET
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
Feb 2019
→ Jul 2029
Phase 1Current
NCT06603928
279 pts·Endometrial Ca
2019-02→2029-07·Active
NCT06485283
1,202 pts·ET
2020-09→TBD·Terminated
1,481 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-07-053.3y awayInterim· Endometrial Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1
Active
P1
Termina…
Catalysts
Interim
2029-07-05 · 3.3y away
Endometrial Ca
ActiveTerminated|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT06603928Phase 1Endometrial CaActive279BodyWt
NCT06485283Phase 1ETTerminated1202SRI-4
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-1944PfizerNDA/BLAAPOC3HPK1i
DoxacapivasertibEli LillyPhase 3APOC3MDM2i
NVS-6360NovartisApprovedCD38FXIai
MRK-3745Merck & CoPhase 2WRNFXIai
AZN-1715AstraZenecaPhase 3AHRFXIai
AZN-6294AstraZenecaPhase 2/3APOC3CD47i
BMY-9931Bristol-Myers SquibbPhase 1GPRC5DFXIai
ZanutinibBristol-Myers SquibbPhase 2/3APOC3BiTE
NVO-7877Novo NordiskPreclinicalGPRC5DFXIai
TAK-8730TakedaPhase 2VEGFFXIai